| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/04/2010 | US20100056528 Sulfonamide derivatives with therapeutic indications |
| 03/04/2010 | US20100056525 5- and 6- substituted benzimidazole thiophene compounds |
| 03/04/2010 | US20100056523 Inhibitors of akt activity |
| 03/04/2010 | US20100056517 Arylsulfonamide compounds |
| 03/04/2010 | US20100056512 Pyrimidine compounds |
| 03/04/2010 | US20100056510 Macrocyclic Compound |
| 03/04/2010 | US20100056507 Phenyl derivatives and their use as a medicament |
| 03/04/2010 | US20100056505 Substituted Pyrazalones |
| 03/04/2010 | US20100056495 Dimeric iap inhibitors |
| 03/04/2010 | US20100056482 Calixarene Derivatives as Anticancer Agent |
| 03/04/2010 | US20100056468 Pyrimidine Derivatives As Anticancer Agents |
| 03/04/2010 | US20100056466 2'-Cyanopyrimidine Nucleoside Compound |
| 03/04/2010 | US20100056457 Zinc Finger Binding Domains for CNN |
| 03/04/2010 | US20100056448 Glut-1 as a receptor for htlv envelopes and its uses |
| 03/04/2010 | US20100056439 Ligands that have binding specificity for egfr and/or vegf and methods of use therefor |
| 03/04/2010 | US20100056435 Depsipeptides and Their Therapeutic Use |
| 03/04/2010 | US20100056434 Depsipeptides and Their Therapeutic Use |
| 03/04/2010 | US20100056432 Template-fixed peptidomimetics with antibacterial activity |
| 03/04/2010 | US20100056431 Medical uses |
| 03/04/2010 | US20100055696 DRG11-Responsive (DRAGON) Gene Family |
| 03/04/2010 | US20100055687 Mutations in the BCR-ABL tyrosine kinase associated with resistance to ST1-571 |
| 03/04/2010 | US20100055183 Trimeprazine and ethopropazine derivatives for promoting bone growth |
| 03/04/2010 | US20100055167 Stem cell delivery of anti-neoplastic medicine |
| 03/04/2010 | US20100055165 Liposomal gel phthalocyanine preparation for photodynamic therapy of tumors and its manufacturing |
| 03/04/2010 | US20100055136 Tumour Vaccine Comprising Allogenic or Xenogeneic Tumour Cells |
| 03/04/2010 | US20100055120 Prostate stem cell antigen (psca) variants and subsequences thereof |
| 03/04/2010 | US20100055117 Allorestricted peptide-specific t cells |
| 03/04/2010 | US20100055111 Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
| 03/04/2010 | US20100055108 Drug for treating gastric cancer |
| 03/04/2010 | US20100055099 Diagnostics and Treatments for VEGF-Independent Tumors |
| 03/04/2010 | US20100055097 Stable lyophilized pharmaceutical formulation of igg antibodies |
| 03/04/2010 | US20100055095 Genetic variations associated with tumors |
| 03/04/2010 | US20100055094 Pharmaceutical combinations of 1-cyclopropyl-3- [3-(5-m0rphoolin-4-yl-methyl-1h-benzoimidazol-2-yl)- lh-1-pyrazol-4-yl]- urea |
| 03/04/2010 | US20100055093 Pan-cell surface receptor-specific therapeutics |
| 03/04/2010 | US20100055091 Novel GL-50 Molecules and Uses Therefor |
| 03/04/2010 | US20100055090 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| 03/04/2010 | US20100055069 Hpv-18-based papillomavirus vaccines |
| 03/04/2010 | US20100055047 Methods for treating bronchial premalignancy and lung cancer |
| 03/04/2010 | US20100055044 Ruthenium compounds and compositions |
| 03/04/2010 | US20100055034 Human Anti-Folate Receptor Alpha Antibodies and Antibody Fragments for the Radioimmunotherapy of Ovarian Carcinoma |
| 03/04/2010 | US20100055033 Antibody compositions and methods for treatment of neoplastic disease |
| 03/04/2010 | CA2735426A1 New 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis |
| 03/04/2010 | CA2735421A1 Delivery of a cd40 agonist to a tumor draining lymph node of a subject |
| 03/04/2010 | CA2735318A1 Nanoparticles for immunotherapy |
| 03/04/2010 | CA2735279A1 Anti-cd5 antibodies |
| 03/04/2010 | CA2735182A1 Tbc1d7 as tumor marker and therapeutic target for cancer |
| 03/04/2010 | CA2735177A1 Saturated bicyclic heterocyclic derivatives as smo antagonists |
| 03/04/2010 | CA2735118A1 Butyrylcholinesterase ligands as diagnostic tools and treatment for diseases of the nervous system |
| 03/04/2010 | CA2735084A1 Novel polymorphs of sunitinib and processes for their preparation |
| 03/04/2010 | CA2734979A1 Syngr4 for target genes of cancer therapy and diagnosis |
| 03/04/2010 | CA2734965A1 Novel crystalline form and processes for its preparation |
| 03/04/2010 | CA2734551A1 Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors |
| 03/03/2010 | EP2159230A1 Anti-TNF antibodies, compositions, methods and uses |
| 03/03/2010 | EP2158900A1 Polymeric delivery formulations of leuprolide with improved efficacy |
| 03/03/2010 | EP2158318A2 Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| 03/03/2010 | EP2158207A1 Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
| 03/03/2010 | EP2158194A2 Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics |
| 03/03/2010 | EP2157972A1 Methods of treatment using intravenous formulations comprising temozolomide |
| 03/03/2010 | EP1922316B1 Benzimidazole thiophene compounds as plk modulators |
| 03/03/2010 | EP1891102B1 Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12 |
| 03/03/2010 | EP1813289B1 Medicinal composition for treating cancer or diabetes |
| 03/03/2010 | EP1756270B1 Diagnosis and treatment of myeloid and lymphoid cell cancers with chlorotoxin or a derivative |
| 03/03/2010 | EP1753858B1 Novel saccharothrix strain and antibiotics derived therefrom, i.e. mutactimycins and aldgamycins |
| 03/03/2010 | EP1743648B1 Method for treating inflammation |
| 03/03/2010 | EP1675465B1 Improved combination bacteriolytic therapy for the treatment of tumors |
| 03/03/2010 | EP1631295B1 Use of condensed heterocyclic compounds as scce inhibitors for the treatment of skin diseases |
| 03/03/2010 | EP1569656B1 Phosphoantigens for regulating an immune response |
| 03/03/2010 | EP1505973B1 Combinations for treating multiple myeloma |
| 03/03/2010 | EP1107964B1 Isoquinoline derivatives with angiogenesis inhibiting activity |
| 03/03/2010 | EP1100801B1 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric g protein |
| 03/03/2010 | EP0973381B1 Animal model for evaluation of vaccines |
| 03/03/2010 | CN101659639A Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 03/02/2010 | US7671252 Fad4, Fad5, Fad5-2, and Fad6, novel fatty acid desaturase family members and uses thereof |
| 03/02/2010 | US7671180 Heparin binding protein for use in diagnosis, prvention and treatment of cell proliferative, liver, neurodegeneartive, inflammatory and pancreatic disorders; wound healing agents |
| 03/02/2010 | US7671092 Paclitaxel enhancer compounds |
| 03/02/2010 | US7671078 1,3-dicyclohexyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea; 1,3-dicycloheptyl-2-(6,6-dimethyl-5,6-dihydroimidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea; CXC chemokine Receptor |
| 03/02/2010 | US7671059 (S)-2-Amino-6-benzyl-7-[4-fluoro-2-(2-fluoro-pyridin-3-yl)-phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one;cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases |
| 03/02/2010 | US7671054 Reverse-turn mimetics and method relating thereto |
| 03/02/2010 | US7671042 Pharmaceutical compositions containing cyclodextrins and taxoids |
| 03/02/2010 | US7671040 Concurrent administering cancer drug and glucan; synergistic mixture |
| 03/02/2010 | US7671035 Epidermal growth factor receptor antisense oligonucleotides |
| 03/02/2010 | US7670829 from a simple carbon source; includes 17 alpha -hydroxypregnenolone, cortisol, cortexolone, 17 alpha -hydroxyprogesterone, and derivatives; genetic engineering |
| 03/02/2010 | US7670767 Genetic alterations associated with cancer |
| 03/02/2010 | US7670632 Saponin mixtures and compounds isolated from Acacia victoriae; glycosides of acacic or oleanolic acid; control of cell apoptosis and cytotoxicity; antitumor, -carcinogenic, -inflammatory and -proliferative agents; atherosclerosis |
| 03/02/2010 | US7670611 Cancer immunotherapy with semi-allogeneic cells |
| 03/02/2010 | US7670601 Using uterine tumor specific marker as diagnostic tool in detection of urogenital specific cell proliferative disorders |
| 03/02/2010 | US7670599 Using monoclonal antibody as diagnostic and therapeutic tool in treatment and prevention of cell proliferative and degenerative bone disorders; immunotherapy |
| 03/02/2010 | US7670598 Method for limiting the growth of cancer cells using an attenuated measles virus |
| 03/02/2010 | CA2394615C Substituted 1,3,4-oxadiazoles and a method of reducing tnf-.alpha. levels |
| 03/01/2010 | CA2640879A1 Liquid formulation containing a taxane derivative |
| 02/25/2010 | WO2010022358A1 6-substituted 2-(benzimidazolyl)purine and purinone derivatives and 6-substituted 2-(imidazoio[4,5- c]pyridinyl)purine and purinone derivatives for immunosuppression |
| 02/25/2010 | WO2010022277A2 Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers |
| 02/25/2010 | WO2010022249A2 Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
| 02/25/2010 | WO2010022243A1 Chemoprevention of head and neck squamous cell carcinomas |
| 02/25/2010 | WO2010022143A2 Assessing and treating breast cancer patients |
| 02/25/2010 | WO2010022120A1 Human antibodies to human rankl |
| 02/25/2010 | WO2010022089A2 Derivatives of apf and methods of use |
| 02/25/2010 | WO2010022081A1 Triazolopyridine compounds as pim kinase inhibitors |
| 02/25/2010 | WO2010022051A2 Disruptors of early/recycling endosomes |
| 02/25/2010 | WO2010021934A2 Azaindole inhibitors of iap |